GEN MUHANDISLIGI YORDAMIDA IRSIY KASALLIKLARNI DAVOLASH.
Keywords:
Gen muhandisligi, gen terapiyasi, genom tahriri, CRISPR-Cas9, irsiy kasalliklar, molekulyar tibbiyot, somatik hujayra tahriri, germinal liniya, biotexnologiyaAbstract
Ushbu maqolada gen muhandisligi texnologiyalarining irsiy kasalliklarni aniqlashprofilaktika qilish hamda davolashdagi o‘rni ilmiy yondashuv asosida tahlil qilinadi. Genom tahriri xususan CRISPR-Cas9, TALENs va ZFN kabi texnologiyalarning imkoniyatlari, ularning afzallik va xavflari, klinik tadqiqotlarda qo‘llanilishi keng yoritiladi. Tadqiqot natijalari gen terapiyasining kelajakda shaxsiy
tibbiyot, prenatal diagnostika va genomni modifikatsiya qilish orqali irsiy kasalliklarni kamaytirishdagi strategik ahamiyatini ko‘rsatadi.
References
1. Doudna, J. A., & Charpentier, E. (2014). Genome editing: The new frontier of genetics. Science, 346(6213), 1258096.2.
Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6), 1262–1278. 3.
Carroll, D. (2008). Zinc-finger nucleases: A review of their structure and applications. Nature Reviews Molecular Cell Biology, 9(1), 8–20.4.
Joung, J. K., & Sander, J. D. (2013). TALENs: A widely applicable technology for targeted genome editing. Nature Reviews Molecular Cell Biology, 14(1), 49–55.5. Gillmore, J. D., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502. 6. Frangoul, H., et al. (2020). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 383(26), 2520–2530.7. Porteus, M. (2019). A new class of medicines through DNA editing. New England Journal of Medicine, 380(10), 947–959.8. Cox, D. B. T., Platt, R. J., & Zhang, F. (2015). Therapeutic genome editing: Prospects and challenges. Nature Medicine, 21(2), 121–131.
